skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

45 Total results for product and free and sample content found

Datamonitor Healthcare

Alnylam and partner Sanofi deliver on their RNAi promise with groundbreaking results in rare polyneuropathy condition

By Zara Fulton 08 Oct 2017

Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.

Topic BioPharmaceutical

Datamonitor Healthcare

Allergan uses Native American tribe’s sovereign immunity to delay generic entry

By Zara Fulton 08 Oct 2017

Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.

Topic Company analysis

Datamonitor Healthcare

Gilead expands into CAR-T therapy with $11.9bn purchase of Kite Pharmaceuticals

By Oliver Spray 08 Oct 2017

Pharmavitae Analytics expects Gilead’s purchase of Kite to generate long-term growth for Gilead.

Topic Company analysis

Datamonitor Healthcare

Xtandi will have first-mover advantage in non-metastatic prostate cancer setting

By Edward Thomason 08 Oct 2017

Positive results from the Phase III PROSPER trial (ClinicalTrials.gov identifier

Topic Cancer

Medtech Insight

UK Viewpoint: Tech & Innovation In Focus In NHS Chief's 'Forward View'

By Ashley Yeo 04 Apr 2017

Filtering out the background noise, NHS England's chief executive tends to give a straightforward account of the state and the needs of the national health care provider. He did just that in a mid-term update of the NHS Five Year Forward View on March 31.

Datamonitor Healthcare

Ocrevus FDA approval marks watershed moment for MS market

03 Apr 2017

Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).

Topic FDA Multiple Sclerosis

Datamonitor Healthcare

Disappointing Translarna failure is an isolated event for CF pipeline

30 Mar 2017

PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.

Topic Comment wire

Datamonitor Healthcare

After several setbacks, Xadago has received a less than ideal FDA approval in Parkinson’s disease

By Stephanie Yip 28 Mar 2017

On 21 March 2017, Newron Pharmaceuticals and its partners Zambon and US WorldMeds announced the approval of Xadago (safinamide) for the treatment of Parkinson’s disease (PD) as an add-on therapy to levodopa/carbidopa for patients experiencing “off” periods (BusinessWire, 2017; FDA press release, 2017). This approval was long-awaited by Newron and its US partner, US WorldMeds, as it followed numerous earlier US regulatory setbacks. Newron and its partner are now looking to successfully launch Xadago, but the US approved label fell short of ideal as it did not extend to early-stage PD patients receiving dopamine agonists  

Topic Diseases Parkinsons disease

Datamonitor Healthcare

Potential to be a disease modifier gives Cosentyx a competitive edge in the psoriasis market

By Ines Mihel 27 Mar 2017

At the 2017 annual meeting of the Maui Derm for Dermatologists, Novartis presented new data from the A2302E1 study which suggest that Cosentyx (secukinumab) could change the course of psoriasis, with approximately 20% of patients achieving maintenance of skin clearance after stopping treatment for one year. Datamonitor Healthcare believes that these data could allow Cosentyx to be positioned earlier in the treatment algorithm and become a market leader in psoriasis.

Topic Diseases Psoriatic arthritis

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: